Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)

BACKGROUND: Fimasartan (Kanarb; Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea) is a non-protein angiotensin II receptor blocker that selectively blocks the AT1 receptor. No prior large-scale study has investigated the impact of demographics, disease, treatment, and clinical characterist...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Dong Joo, Han, Su-Eun, Jeong, Seung Hee, Hong, Myung Sook, Choe, Seong Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119343/
https://www.ncbi.nlm.nih.gov/pubmed/30186623
http://dx.doi.org/10.1186/s40885-018-0096-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119343/
https://www.ncbi.nlm.nih.gov/pubmed/30186623
http://dx.doi.org/10.1186/s40885-018-0096-2

Ejemplares similares